Silence Therapeutics PLC (LON:SLN), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, said it will announce its unaudited interim results for the half-year ended June 30, 2020, on September 14, 2020. It noted that Iain Ross, the group's executive chairman, Dr Rob Quinn, its chief financial officer and Dr Giles Campion, head of R&D and the chief medical officer will host a webcast and live conference call for analysts and investors at 1.00pm BST/8.00am ET on the day of the results.